Market Access
nine for 2023

Nine for 2023, part three: thriving or surviving?

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry

Sales & Marketing

Digital

Market Access

Editor's Picks

  1. Axsome breaks new ground in Alzheimer's with Auvelity OK
  2. Merck partners Remepy in PDURS-focused alliance
  3. Teva makes its first M&A play in years, buying Emalex
  4. UK study finds clue to rising cancer rates in younger people
  5. Boehringer/Zealand dual-acting drug causes 16.6% weight loss

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

Patients
Anatomical graphic concept of a liver in 3D

Rewriting the MASLD playbook

Effective care now requires identifying metabolic risks early and addressing the broader factors driving liver damage.

more

R&D

more